Olopatadine/mometasone

Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray in Singapore, Hong Kong and Vietnam

Retrieved on: 
Thursday, January 20, 2022
SEA, Allergic rhinitis, Nasal congestion, Dermatology, Glenmark Pharmaceuticals, CVS, Industry, Yuhan, Corporate sustainability, AR, Prevalence, Itch, Rhinitis, Season, American Journal, US FDA, United Kingdom, Sneeze, Partnership, Mometasone, Menarini, Otorhinolaryngology, Patient, Nasal mucosa, CNS, SAR, OH, US, Brazil, Biosimilar, Review, Glenmark, Allergic inflammation, Dow Jones, DJSI, Bausch Health, Tablet, Health Canada, OTC, Olopatadine, Risk, DCP, Index, Bank, Pharmaceutical industry, Fine chemical, Olopatadine/mometasone, EU, Lotus, National Medical Products Administration

Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris, while Lotus International Pte.

Key Points: 
  • Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris, while Lotus International Pte.
  • MUMBAI, India, Jan. 20, 2022 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven, global, integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Lotus International Pte.
  • Ltd., a wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd. (Lotus), for commercializing its innovative nasal sprayRyaltrisinSingapore, Hong Kong and Vietnam.
  • Glenmark will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus.

Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age an

Retrieved on: 
Friday, January 14, 2022
Medicine, Taste, New Drug Application, Menarini, NDA, Patient, DJSI, Bausch Health, Rhinitis, Czech Republic, Breast milk, OH, Virus, Allergy, Biosimilar, Safety, Health Canada, Dermatology, Review, Nose, Glenmark, United Kingdom, Fungus, Tuberculosis, Skin, Bacteria, Recurrence, Industry, Infection, Index, Olopatadine, Pregnancy, Measles, Risk, Immune system, Corporate sustainability, Dow Jones, FDA, DCP, Physician, Mometasone, Pharmaceutical industry, Fine chemical, Vaccine, Petroleum jelly, Birth control, EU, Olopatadine/mometasone

"With this NDA approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms."

Key Points: 
  • "With this NDA approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms."
  • Ryaltris is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved by the FDA for the treatment of symptoms associated with Seasonal Allergic Rhinitis.
  • The combination drug product nasal spray is indicated for the treatment of symptoms associated with seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older.
  • The safety and effectiveness of Ryaltris in pediatric patients younger than 12 years of age has not been established.